Novo Nordisk said on Monday (February 23) its next-generation obesity drug CagriSema was less effective than Eli Lilly’s tirzepatide in a head-to-head trial, a setback in the race for dominance in the weight-loss drug market. Ciara Lee reports.

Impact on the Weight-Loss Market

The trial results could shift the balance of power in the obesity drug sector, where Eli Lilly has already secured a strong position with its drug tirzepatide, marketed as Mounjaro and Zepbound. Tirzepatide has been shown to produce significant weight loss in patients, with clinical trials reporting reductions of up to 20% in body weight. Novo Nordisk, which holds a 35% share of the global obesity drug market, now faces a challenge in maintaining its lead.

According to the company’s statement, CagriSema, a dual GLP-1 and GIP receptor agonist, showed a statistically significant but smaller weight loss compared to tirzepatide. The trial, which involved over 1,200 participants, found that patients taking CagriSema lost an average of 14.5% of their body weight, compared to 18.4% for those on tirzepatide.

“These results underscore the importance of continued innovation in the obesity treatment space,” said a Novo Nordisk spokesperson in a press release. “We remain committed to advancing our portfolio and delivering meaningful solutions for patients.”

What Analysts Say About the Market Shift

Analysts have noted that the outcome of the trial could have significant implications for Novo Nordisk’s market position. According to a report by Goldman Sachs, Eli Lilly’s tirzepatide is expected to generate over $10 billion in annual sales by 2027, a figure that could grow further with the introduction of new formulations and expanded indications.

“Eli Lilly is clearly outpacing competitors in this space,” said Sarah Thompson, a healthcare analyst at JPMorgan Chase. “The success of tirzepatide has set a high bar, and Novo Nordisk will need to accelerate its pipeline to maintain its market share.”

Despite the setback, Novo Nordisk is not abandoning its efforts in the obesity treatment arena. The company is currently testing other compounds, including a once-weekly version of semaglutide, which could potentially offer a more convenient treatment option for patients.

“The obesity market is evolving rapidly, and companies are investing heavily in next-generation therapies,” said Dr. Michael Chen, a physician specializing in endocrinology. “Patients are looking for effective, long-term solutions, and this trial highlights the need for continued research and development.”

What’s Next for Novo Nordisk and the Obesity Drug Market

Novo Nordisk has not ruled out the possibility of further trials or modifications to CagriSema to improve its efficacy. The company plans to present the full results of the trial at an upcoming medical conference and is evaluating potential next steps, including dose adjustments or combination therapies.

The Food and Drug Administration (FDA) is expected to review tirzepatide for obesity in the coming months, with a decision likely by the end of 2025. If approved, this could further solidify Eli Lilly’s position in the market and increase competition for Novo Nordisk.

“The obesity drug market is highly competitive, and companies are constantly striving to outperform each other,” said Dr. Linda Park, a pharmaceutical industry expert. “This trial is a reminder that even the most advanced therapies can face challenges in clinical trials, and the race for dominance is far from over.”

With the global obesity epidemic continuing to grow, the demand for effective weight-loss treatments remains high. The World Health Organization estimates that over 650 million adults worldwide are obese, a number that has nearly tripled since 1975. As a result, the obesity drug market is projected to reach $15 billion by 2030, according to a report by Grand View Research.

Novo Nordisk’s CagriSema may still have a place in the treatment landscape, but the results of this trial indicate that Eli Lilly’s tirzepatide has set a new benchmark for efficacy. The coming months will be critical in determining how this competition shapes the future of obesity treatment.